All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Now you can personalise
your PsO and PsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing key updates to the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recommendations for the treatment of psoriatic arthritis.
The original GRAPPA guidelines were published in 2009 and revised in 2015.1 These new, updated, 2021 guidelines aim to offer recommendations for the use of therapies for the six psoriatic arthritis domains (peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease), giving guidance on treatments that can and cannot be used with associated conditions (inflammatory bowel disease and uveitis) and other comorbidities. Subcommittees were formed from GRAPPA members, with systemic literature searches completed using data published between 2013 and 2020. Treatment pathway recommendations consider the domains involved in psoriatic arthritis, patient treatment preferences, and current therapies. Additional position statements were added to address treatment with biosimilars and tapering, plus a revised research agenda.1
To download this visual abstract, click below.Download here
In the 24-week results of the SPIRIT-P1 and SPIRIT-P2 trials, IXE demonstrated efficacy when used as a monotherapy and in combination with methotrexate. Here, we discuss the...
Currently, treatment options for PsA include several disease-modifying antirheumatic drugs (DMARDs),...
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox